Source-grounded facts extracted from Vaxart, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vaxart, Inc. reported the first quarter of 2026 results: revenue $39.2 million, net income $5.2 million, EPS $0.02.
“funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the first quarter of 2026 was $39.2 million, compared to $20.9 million for the first quarter of 2025. Revenue in the first quarter of 2026 and the first quarter of 2025 was primarily from government contracts related to”
Vaxart, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25.0 million (effective 2026-04-16).
“On April 16, 2026, Vaxart, Inc. (the “Company”) entered into a purchase agreement (the “ Purchase Agreement ”) and a registration rights agreement (the “ Registration Rights Agreement ”), with Lincoln Park Capital Fund, LLC (“ Lincoln Park ”), pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock”
Vaxart, Inc. terminated Lease Agreement with Britannia Pointe Grand Limited Partnership valued at Termination of Lease Agreement effective May 15, 2026 (effective 2025-12-18).
“On December 18, 2025, Vaxart, Inc., a Delaware corporation (the “Company”), entered into a termination agreement (the “Termination Agreement”) with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership (the “Landlord”), in connection with the termination of that certain lease agreement, by and between the Landlord and the Company, dated September 17, 2021 (the “Lease”) for certain premises located at 170 Harbor Way, South San Francisco, California 94080 that served as the Company’s headquarters.”
Vaxart, Inc. received a nasdaq delisting notice notice regarding other.
“September 19, 2025, the Company received a letter from the Office of the General Counsel of Nasdaq, stating that the Company’s securities will be delisted from Nasdaq as a result of the Company’s noncompliance with the Panel’s Conditions. Trading in the Company’s common stock on Nasdaq was suspended at the open of trading on July 8, 2025. The Company’s common stock is currently quoted on the OTCQX® Best Market under the symbol “VXRT.” SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unde”
Vaxart, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).
“to timely request a hearing by July 8, 2025, then the Hearings Department will take action to follow procedures to delist the Company’s common stock. The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series and is considering all options with regard to its stock listing, including efforts to regain compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will stay delisting but will not stay the tra”
Jeroen Grasman was appointed as Chief Financial Officer at Vaxart, Inc..
“On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.”
Phillip Lee resigned as Chief Financial Officer at Vaxart, Inc..
“On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.”
Robert A. Yedid resigned as Director at Vaxart, Inc..
“Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025”
Kevin Finney was appointed as Director at Vaxart, Inc..
“the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025”
Steven Lo was appointed as Chief Executive Officer, President, and director at Vaxart, Inc..
“On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).”
Michael J. Finney changed role as Interim President and Chief Executive Officer at Vaxart, Inc..
“In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.